Every Form 4 that Guardant Health, Inc. (GH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GH filings page.
Guardant Health, Inc. director Manuel Hidalgo Medina reported an open-market sale of 1,000 shares of Common Stock at an average price of $130.0601 per share. After this transaction on May 28, 2026, he directly holds 639 shares of Guardant Health common stock.
Guardant Health, Inc. Chief Legal Officer John G. Saia reported selling 10,000 shares of common stock in open-market transactions on May 27, 2026. The filing shows two sales: 6 shares at $126.08 per share and 9,994 shares at $125.083 per share.
A footnote explains that the reported price reflects a weighted average, with individual trades executed between $125.00 and $125.44 per share. The insider remains a shareholder after these sales, but the exact remaining position is not detailed in the provided data.
Guardant Health Chief Commercial Officer Chris Freeman exercised options to acquire 24,406 shares of common stock at $32.86 per share and on the same day completed an open-market sale of 24,406 shares at a weighted average price of $118.6741.
After these transactions, Freeman directly holds 60,034 shares of common stock and 701 remaining stock options with a $32.86 exercise price expiring on June 9, 2033. The exercised options come from a June 9, 2023 award that vests over three years.
Guardant Health, Inc. Chief Legal Officer John G. Saia reported open-market sales of a total of 20,000 shares of common stock on May 20, 2026. The shares were sold in three separate transactions at weighted average prices around $105–$107 per share, each executed across multiple trades within narrow intraday price ranges. These transactions reduce his direct holdings but he continues to own Guardant Health stock after the sales.
Guardant Health, Inc. disclosed that the Talasaz and Eskandari 2017 Family Trust, an entity associated with Co-Chief Executive Officer AmirAli Talasaz, completed a series of open-market sales of the company’s common stock.
The filing shows that the trust sold a total of 210,000 shares of Guardant Health common stock on May 20, 2026, across multiple trades. Reported weighted-average sale prices ranged from about $100.95 to about $112.76 per share, with detailed trade-by-trade pricing available on request from the company or the SEC staff. Following these transactions, the trust held 1,886,504 shares of Guardant Health common stock indirectly attributable to Talasaz.
Guardant Health, Inc. director Ian T. Clark reported an indirect open-market sale of the company’s Common Stock. On May 20, 2026, a family trust associated with him sold 6,876 shares at a weighted average price of $106.9006 per share, in multiple trades between $106.85 and $106.99. Following the transaction, the trust held 2,975 shares of Guardant Health Common Stock indirectly on his behalf, and no derivative securities were reported in this filing.
Guardant Health director Manuel Hidalgo Medina reported an option exercise and related stock sales. On May 20, 2026, he exercised stock options to acquire 1,000 shares of common stock at an exercise price of $32.55 per share.
That same day, he completed open-market sales totaling 1,250 shares of common stock, including 250 shares at a weighted-average price of $107.073 per share and 1,000 shares at $107.0956 per share. After these transactions, he directly holds 1,639 shares of Guardant Health common stock and 13,029 stock options with a $32.55 exercise price that expire on July 17, 2034.
Guardant Health director Tariq Musa exercised equity awards and made a small stock sale. On May 15, 2026, 250 restricted stock units converted into common shares, and on May 18, 2026 he sold 116 common shares at $95.96 each, leaving 8,662 shares held directly.
Guardant Health director Manuel Hidalgo Medina exercised restricted stock units into common shares as part of his equity compensation. On May 17, 2026, 232 RSUs converted into 232 shares of common stock at a stated price of $0.00 per share, reflecting a vesting event rather than an open-market purchase.
Following the transaction, he held 1,889 shares of common stock directly and 6,033 restricted stock units. The RSU grant, awarded on July 17, 2024, vests over four years, with 25% vesting on July 17, 2025 and the remaining 75% vesting monthly over the subsequent three years.
Guardant Health Chief Technology Officer Darya Chudova had 8,705 Restricted Stock Units convert into Common Stock on May 15, 2026. To cover tax obligations, 4,679 shares of Common Stock were retained by Guardant Health, and she now directly holds 74,402 shares.
Guardant Health, Inc. Co-Chief Executive Officer and director AmirAli Talasaz reported an open-market sale of 50,000 shares of Common Stock on May 12, 2026. The shares were sold at a weighted average price of $100.32 per share in multiple trades.
After this transaction, 2,096,504 shares of Guardant Health Common Stock are reported as indirectly owned, held by the Talasaz and Eskandari 2017 Family Trust.
Guardant Health, Inc. director Steve E. Krognes exercised restricted stock units into common stock in a routine compensation-related transaction. On April 30, 2026, 154 common shares were acquired upon RSU vesting, bringing his direct common stock holdings to 19,362 shares.
The RSUs originated from an award granted on August 9, 2022, with 25% vesting on June 30, 2023 and the remaining 75% vesting in substantially equal monthly installments over three years. After this vesting event, he holds 309 restricted stock units directly.
Guardant Health, Inc. director Roberto Mignone acquired 264 common shares through RSU vesting. On April 21, 2026, 264 Restricted Stock Units converted into 264 shares of common stock at a stated price of $0.00 per share, reflecting equity compensation rather than an open-market purchase or sale.
Following the transaction, Mignone directly holds 4,751 shares of common stock and 7,920 Restricted Stock Units. The RSUs come from an award granted on November 8, 2024 that vests over four years. According to the award terms, 25% of the RSUs vested on October 21, 2025, and the remaining 75% vests in equal monthly installments over the next three years.
Guardant Health director Manuel Hidalgo Medina exercised restricted stock units into common shares. On April 17, 2026, he acquired 232 shares of Guardant Health, Inc. common stock through a derivative exercise at a stated price of $0.00 per share.
Following the transaction, he directly holds 1,657 shares of common stock and 6,265 restricted stock units. The RSU award, granted on July 17, 2024, vests over four years, with 25% vesting on July 17, 2025 and the remaining 75% vesting monthly over the subsequent three years.
Guardant Health director Tariq Musa reported routine equity activity tied to a prior restricted stock unit (RSU) grant. On April 15, 2026, he exercised 250 Restricted Stock Units at $0.00, converting them into 250 shares of Common Stock. On April 16, 2026, he completed an open-market sale of 116 Common Stock shares at an average price of $84.83 per share.
Following these transactions, Musa directly holds 8,528 shares of Common Stock and 2,749 Restricted Stock Units. The RSU award, granted on March 6, 2023, vests over four years, with 25% vesting on March 15, 2024 and the remaining 75% vesting monthly over the next three years.
Guardant Health Chief Legal Officer John G. Saia reported routine equity compensation activity. On April 15, 2026, 7,569 restricted stock units converted into an equal number of Guardant Health common shares at no exercise price as part of a scheduled vesting.
Of these vested shares, 3,970 were retained by the company to satisfy Mr. Saia’s tax withholding obligations at a reference price of $84.86 per share, which is a tax-withholding disposition rather than an open-market sale. After these transactions, he directly owns 65,950 shares of Guardant Health common stock.
Guardant Health Chief People Officer sells shares in open market
Guardant Health, Inc.'s Chief People Officer, Terilyn J. Monroe, reported an open-market sale of 3,832 shares of Common Stock at $92.68 per share. After this transaction, she continues to hold 20,990 Guardant Health shares directly.
Guardant Health Chief Legal Officer John G. Saia reported routine equity compensation activity. On April 1, 2026, multiple tranches of restricted stock units vested and were exercised into a total of 11,461 shares of Common Stock at an exercise price of $0.00 per share.
To cover tax obligations related to the vesting, 6,013 Common Stock shares were retained by Guardant Health at a price of $91.15 per share, as disclosed in the footnotes. After these transactions, Saia directly held 62,351 Common Stock shares. The RSU awards were originally granted between November 2022 and March 2025 and vest over three- to four-year periods in quarterly installments.
Guardant Health, Inc. Chief People Officer Terilyn J. Monroe reported routine equity compensation activity tied to restricted stock units. On April 1, 2026, she acquired 8,019 shares of common stock upon vesting and related derivative exercises, then had 4,187 shares withheld by the company to cover tax obligations at $91.15 per share. After these transactions, she directly held 24,822 shares of common stock. The filing reflects compensation and tax withholding mechanics rather than open-market buying or selling.
Guardant Health Chief Information Officer Kumud Kalia reported routine equity compensation activity involving restricted stock units. On April 1, 2026, several restricted stock unit awards converted into a total of 10,044 shares of Common Stock, reflecting scheduled vesting from previously granted awards.
To cover related tax obligations, 5,092 Common Stock shares were withheld by Guardant Health at $91.15 per share, as described in the footnotes, and were not sold in the open market. After these transactions, Kalia directly holds 49,249 Common Stock shares, indicating an overall increase in his equity stake despite the tax withholding.
Guardant Health Chief Commercial Officer Chris Freeman reported routine equity compensation activity. On April 1, 2026, multiple installments of his restricted stock unit awards vested, resulting in the acquisition of 11,213 shares of Common Stock at an exercise price of $0.00 per share.
To cover tax obligations tied to this vesting, 4,750 shares were withheld by Guardant Health at a price of $91.15 per share, as noted in the footnotes. After these transactions, Freeman directly owned 60,034 shares of Guardant Health common stock. The RSU awards were originally granted between November 7, 2022 and March 12, 2025 and vest over three- to four-year periods in quarterly installments.
Guardant Health, Inc. Chief Medical Officer Craig Eagle reported routine equity compensation activity as several restricted stock unit awards vested on April 1, 2026. He exercised RSUs to acquire a total of 11,400 shares of common stock at an exercise price of $0.00 per share.
To satisfy related tax obligations, 5,779 shares of common stock were retained by the company at $91.15 per share, as described in the footnotes, rather than sold on the open market. Following these transactions, Eagle directly holds 72,001 shares of Guardant Health common stock.
Guardant Health Chief Technology Officer Darya Chudova reported routine equity compensation activity tied to vesting restricted stock units. On April 1, 2026, she acquired a total of 13,029 shares of Guardant Health common stock through the exercise and conversion of multiple restricted stock unit awards at a stated price of $0.00 per share.
To cover tax withholding obligations upon vesting, 7,005 shares were retained by the company at a price of $91.15 per share, as described in the footnotes. After these compensation-related transactions and tax withholding, Chudova directly holds 70,376 shares of Guardant Health common stock.
Guardant Health, Inc. Chief Financial Officer Michael Brian Bell exercised restricted stock units into common shares and had shares withheld for taxes. On April 1, 2026, he converted multiple restricted stock unit awards into a total of 12,777 shares of common stock at a conversion price of $0.00 per share.
In a related tax-withholding transaction, 6,869 common shares were retained by the company at $91.15 per share to satisfy tax liabilities tied to the RSU vesting. After these transactions, Bell directly held 49,509 shares of Guardant Health common stock, reflecting routine equity compensation activity rather than an open-market trade.
Guardant Health, Inc. Co-Chief Executive Officer AmirAli Talasaz reported routine equity compensation activity involving restricted stock units (RSUs) and related common stock on March 31 and April 1, 2026. Several RSU awards vested and were converted into shares of common stock held largely through the Talasaz and Eskandari 2017 Family Trust. In connection with these vestings, a total of 18,515 shares of common stock were withheld by the company at prices of $92.37 and $91.15 per share to satisfy tax withholding obligations, rather than sold in open-market transactions. Following these transactions, the family trust held 2,146,504 shares of Guardant Health common stock, while Talasaz also retained a substantial number of unvested RSUs directly.
Guardant Health, Inc. co-Chief Executive Officer Helmy Eltoukhy reported routine equity compensation activity involving restricted stock units and related common stock. On March 31 and April 1, 2026, multiple restricted stock unit awards converted into an aggregate of tens of thousands of shares of common stock at a $0.00 exercise price.
To cover associated tax obligations upon these vesting events, a total of 18,515 shares of common stock were retained by the company at prices of $92.37 and $91.15 per share, characterized as tax-withholding dispositions rather than open-market sales. Following these transactions, a revocable trust associated with Eltoukhy held 2,112,919 shares of common stock, and he directly held 68,011 restricted stock units. The filing reflects compensation-related vesting and tax withholding, not discretionary market trading.
Guardant Health director Steve E. Krognes acquired 155 shares of Common Stock through the vesting and exercise of Restricted Stock Units. The transaction occurred on March 31, 2026 at an exercise price of $0.00 per share, reflecting a routine equity-compensation event rather than an open-market purchase.
The 155 Restricted Stock Units converted into 155 shares of Common Stock, increasing his direct Common Stock holdings to 19,208 shares following the transaction. He also continues to hold 463 Restricted Stock Units after this vesting. The underlying award was originally granted on August 9, 2022 and vests over four years, with 25% vesting on June 30, 2023 and the remaining 75% vesting in substantially equal monthly installments over the subsequent three years.
Guardant Health director Roberto Mignone reported the vesting and settlement of 264 restricted stock units into an equal number of common shares at a price of $0.00 per share, reflecting a routine equity compensation event rather than an open-market trade.
After this derivative exercise, Mignone directly holds 4,487 shares of common stock and 8,184 restricted stock units. The vested RSUs come from an award granted on November 8, 2024 that vests 25% on the one-year anniversary of October 21, 2024, with the remaining 75% vesting monthly over the following three years.
Guardant Health director Tariq Musa reported an open-market sale of 348 shares of Guardant Health common stock on March 18, 2026, at an average price of $88.09 per share. After this transaction, he directly holds 8,394 shares of the company’s stock.
Guardant Health director Manuel Hidalgo Medina exercised restricted stock units into common shares as part of his equity compensation. On March 17, 2026, 232 restricted stock units converted into 232 shares of common stock at a stated price of $0.00 per share, raising his direct common stock holdings to 1,425 shares. The award originated from a grant on July 17, 2024 that vests over four years, with 25% vesting on the one-year anniversary and the remaining 75% vesting monthly over the following three years.
Guardant Health Co-CEO AmirAli Talasaz reported compensation-related equity activity and trust-related share movements. On March 17, 2026, he received awards of 11,268 and 101,409 restricted stock units that vest over quarterly and multi-year schedules. Earlier, on January 1 and March 13, 2026, performance-based and time-based RSUs covering 38,283 and 26,961 shares were exercised into common stock, with 19,402 and 13,664 shares withheld by the company to cover tax obligations. In connection with these events, 13,209 common shares were transferred from direct ownership into the Talasaz and Eskandari 2017 Family Trust, which held 2,128,489 shares after the March 13, 2026 transactions.
Guardant Health Co-CEO Helmy Eltoukhy reported compensation-related equity activity and trust transfers, not open‑market trading. On March 17, 2026, he received two new restricted stock unit awards covering 11,268 and 101,409 shares of common stock, with multi-year vesting schedules.
On January 1, 2026 and March 13, 2026, performance-based and time-based RSUs were exercised into a total of 65,244 shares of common stock. In connection with these vestings, the company withheld 19,402 and 13,664 shares to cover tax obligations, which were not market sales.
The filing also records a transfer of 13,209 shares from direct ownership to the Helmy A. Eltoukhy Revocable Trust, after which the trust held 2,094,904 shares. Overall, the transactions increase his equity-based compensation and shift holdings into a revocable trust while maintaining a substantial indirect position.
Guardant Health director Tariq Musa exercised restricted stock units into common shares as part of a scheduled vesting. On March 15, 2026, 249 restricted stock units converted into 249 shares of common stock at a stated price of $0.0000 per share.
Following the transactions, he held 8,742 shares of common stock directly and 2,999 restricted stock units. The underlying restricted stock unit award was granted on March 6, 2023 and vests over four years, with 25% vesting on the one-year anniversary of March 15, 2023 and the remaining 75% vesting monthly over the subsequent three years.
Guardant Health, Inc. Chief Legal Officer John G. Saia reported equity awards vesting and converting into common stock on March 15, 2026. Performance-based and time-based restricted stock units were exercised under code “M,” delivering additional Guardant Health common shares.
The company retained 4,622 shares at $85.49 per share under code “F” to satisfy Mr. Saia’s tax withholding obligations, as described in the footnotes. After these transactions, he directly owns 56,903 shares of Guardant Health common stock.
Guardant Health, Inc. Chief Information Officer Kumud Kalia exercised equity awards that vested on March 15, 2026. A performance-based restricted stock unit award converted into 12,856 shares of common stock, and a separate restricted stock unit award converted into 637 shares of common stock, both at a price of $0.00 per share.
The company withheld 6,839 shares of common stock at $85.49 per share to satisfy tax obligations related to the vesting, which is treated as a tax-withholding disposition rather than an open-market sale. After these transactions, Kalia directly held 44,297 shares of Guardant Health common stock.
Guardant Health, Inc. Chief Commercial Officer Chris Freeman exercised performance-based and time-based restricted stock units into common stock. On March 15, 2026, 15,426 performance-based RSUs and 1,402 RSUs converted into an equal number of common shares at a conversion price of $0.00 per share. To cover tax withholding obligations on this vesting, 7,127 common shares were retained by the company at $85.49 per share, as a tax-withholding disposition rather than an open-market sale. Following these transactions, Freeman directly holds 53,571 shares of Guardant Health common stock. The performance-based award was granted on June 7, 2023 with a three-year performance metric, and the RSU award was granted on June 9, 2023 with vesting over three years.
Guardant Health Chief Medical Officer Craig Eagle exercised and vested stock awards, with part withheld for taxes. On March 15, 2026, performance-based and time-based restricted stock units covering 13,712 and 1,402 shares of common stock, respectively, were converted into common shares at no exercise price. The company retained 7,661 shares of common stock at $85.49 per share to satisfy Dr. Eagle’s tax withholding obligations related to this vesting, rather than selling shares on the open market. Following these transactions, Dr. Eagle directly holds 66,380 shares of Guardant Health common stock. No remaining derivative awards related to these units are shown after this filing.
Guardant Health Chief Technology Officer Darya Chudova exercised performance-based equity and had shares withheld for taxes. On March 15, 2026, a performance-based restricted stock unit award covering 10,714 units converted into 10,714 shares of common stock after the second performance tranche was achieved.
The company then withheld 5,759 of those common shares, valued at $85.49 per share, to cover tax obligations associated with the vesting, as disclosed in the footnotes. After these transactions, Chudova directly held 64,352 shares of Guardant Health common stock, reflecting a routine compensation-related equity increase rather than an open-market trade.
Guardant Health, Inc. Chief Financial Officer Michael Brian Bell reported a mix of equity compensation vesting and share dispositions. On March 15, 2026, restricted stock units and performance-based restricted stock units covering a total of 13,790 shares of Common Stock vested and were converted at a $0.0000 exercise price. To satisfy tax obligations on this vesting, 7,413 shares were withheld by the company at a price of $85.4900 per share. On March 16, 2026, Bell completed an open-market sale of 3,000 shares of Common Stock at a weighted average price of $87.0370 per share. After these transactions, he directly holds 43,601 shares of Guardant Health Common Stock.
Guardant Health, Inc. reported that Chief Legal Officer John G. Saia received a grant of 20,448 restricted stock units tied to Guardant Health common stock. These RSUs were awarded on March 11, 2026 as part of his equity compensation and do not involve any cash share purchases or sales.
According to the vesting schedule, 33% of the RSUs will vest on April 1, 2027, with the remaining 67% vesting in equal quarterly installments over the following two years. After this grant, Saia directly holds 20,448 RSUs, which will convert into common shares only as they vest.
Monroe Terilyn J. reported acquisition or exercise transactions in this Form 4 filing.
Guardant Health, Inc. reported that Chief People Officer Terilyn J. Monroe received a grant of 17,040 Restricted Stock Units on March 11, 2026. These RSUs represent the right to receive an equal number of Guardant common shares as they vest over time.
According to the award terms, 33% of the RSUs will vest on April 1, 2027, and the remaining 67% will vest in equal quarterly installments over the following two years. After this grant, Monroe holds 17,040 RSUs directly, reflecting a routine equity compensation award rather than an open‑market purchase or sale.
Kalia Kumud reported acquisition or exercise transactions in this Form 4 filing.
Guardant Health, Inc. reported that Chief Information Officer Kalia Kumud received a grant of 13,632 restricted stock units (RSUs) on March 11, 2026. The award vests over three years: 33% on April 1, 2027, with the remaining 67% vesting in equal quarterly installments over the following two years. After this grant, Kumud holds 13,632 RSUs directly.
Freeman Chris reported acquisition or exercise transactions in this Form 4 filing.
Guardant Health, Inc. reported that Chief Commercial Officer Chris Freeman received a grant of 18,744 restricted stock units. These RSUs, which represent rights to receive an equal number of common shares, were awarded as compensation and involve no cash purchase or market trade.
The award granted on March 11, 2026 vests over three years: 33% of the units vest on April 1, 2027, with the remaining 67% vesting in equal quarterly installments over the following two years. After this grant, Freeman holds 18,744 RSUs directly.
Guardant Health, Inc. Chief Technology Officer Darya Chudova reported a grant of 23,856 restricted stock units. The award was granted on March 11, 2026 and will convert into an equal number of common shares as it vests. According to the vesting schedule, 33% of the units will vest on April 1, 2027, with the remaining 67% vesting in equal quarterly installments over the following two years. After this grant, her reported direct holdings in this award total 23,856 restricted stock units.
Bell Michael Brian reported acquisition or exercise transactions in this Form 4 filing.
Guardant Health, Inc. Chief Financial Officer Michael Brian Bell received a grant of 26,582 restricted stock units on March 11, 2026 as equity compensation. The award vests over three years: 33% on April 1, 2027 and the remaining 67% in equal quarterly installments over the following two years, settling in common stock as units vest.
Guardant Health, Inc. director Manuel Hidalgo Medina reported option exercises and share sales in company stock. On March 6, 2026, he exercised a stock option for 1,000 shares at a price of $0.00 per share, receiving 1,000 shares of common stock valued at $32.55 per share in the transaction record.
The same day, he sold a total of 1,300 shares of common stock in open-market transactions at average prices of $91.6065 and $91.3001 per share, leaving him with 1,193 common shares held directly after the sales. The underlying stock option was originally granted on July 17, 2024 and vests over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years.
Guardant Health Chief Information Officer Kumud Kalia exercised stock options and sold shares on March 4, 2026. He exercised multiple stock option awards, converting them into common stock at exercise prices including $47.20, $74.00, $32.86, $28.37, and $28.61 per share.
On the same date, he sold a total of 40,000 shares of Guardant Health common stock in open-market transactions at weighted average prices of about $95.12 and $95.73 per share, across ranges disclosed in the footnotes. After these trades, he directly held 37,643 shares of common stock.
The option awards he exercised were originally granted between April 20, 2020 and November 8, 2024 and vest over three- or four-year schedules, with initial portions vesting on specified dates and remaining shares vesting in equal monthly installments thereafter.
Guardant Health director Steve E. Krognes reported the vesting and conversion of restricted stock units into common shares. On August 9, 2022 he received a restricted stock unit award that began vesting June 30, 2023, with 25% vesting then and the remaining 75% vesting in equal monthly installments over three years. On February 28, 2026, 154 restricted stock units vested and were converted at no cost into 154 shares of Guardant Health common stock. After these transactions, he directly held 618 restricted stock units and 19,053 shares of common stock.
Guardant Health director Roberto Mignone reported the vesting and settlement of 264 restricted stock units on February 21, 2026. These units, granted on November 8, 2024, convert into common stock at no cost as part of a four-year equity award vesting schedule.
Guardant Health director Manuel Hidalgo Medina reported acquiring shares through equity awards. On the vesting of a restricted stock unit grant on July 17, 2024, 232 restricted stock units converted into 232 shares of common stock at a price of $0.00 per share, reflecting an exercise or conversion of a derivative security rather than an open-market purchase. After these transactions, he directly holds 6,729 restricted stock units and 1,493 shares of common stock. The award vests over four years, with 25% vesting on the one-year anniversary of July 17, 2024 and the remaining 75% vesting monthly over the following three years.